1. Introduction {#sec1}
===============

The root of ginseng (*Panax ginseng* Meyer) has been traditionally used for medicine and food. The primary physiologically-active substances of ginseng are ginsenosides, polyacetylenes, ginseng proteins, polysaccharides, and phenolic compounds. Ginsenosides in particular have been identified as the principal component of ginseng, displaying various biochemical and pharmacological properties. A number of researchers have studied the components of ginseng since the late 1960s, starting with the research of Shibata et al [@bib1], whose research group identified the chemical structures of ginsenosides. Ginsenoside Re (C~53~H~90~O~22~) is the main ingredient of ginseng berries and roots. Notably, the amount of ginsenoside Re in the berries was four to six times more than that in the roots [@bib2]. Research in the area has shown that ginsenoside Re exhibits multiple pharmacological activities via different mechanisms both *in vivo* and *in vitro* [@bib3; @bib4; @bib5; @bib6; @bib7; @bib8]. However, the pharmacological effects of ginsenoside Re on gastritis or gastric ulcer have not yet been studied.

A gastric ulcer is one of the most common diseases in the world, which affects approximately 5--10% of people during their lives. The therapy used to treat gastric ulcers includes control of acid secretion as well as the inflammation reversal to the mucosa. Korea red ginseng can assist in the eradication of *Helicobacter pylori* and alleviate *H. pylori*-induced halitosis [@bib9]. A recent pharmacological investigation reports the antihistamine and anticytokine releasing effects of ginsenoside Re isolated from the berries of *Panax ginseng* [@bib7].

For the common treatment of mild gastritis, antacids in liquid or tablet form are typically used. When antacids do not provide sufficient relief, H~2~ blocking medications, such as cimetidine, ranitidine, nizatidine, and famotidine, which help reduce the amount of acid are often prescribed [@bib10]. Famotidine, the most potent H~2~ receptor antagonist, was used as a positive control [@bib11].

The present study examined the protective effect of ginsenoside Re on acute gastric mucosal lesion progression in rats treated with compound 48/80 (C48/80). C48/80 causes degranulation of mast cells in connective tissue with the release of histamine from the cells, and causes the development of acute gastric mucosal lesions with neutrophils infiltrating into the gastric mucosal tissue [@bib12; @bib13]. Injecting C48/80 is consequently suggested as a good model for elucidating the mechanisms of clinical acute gastric lesions [@bib14].

2. Materials and methods {#sec2}
========================

2.1. Sample preparation {#sec2.1}
-----------------------

Ginsenoside Re was prepared according to a previously reported method [@bib7]. In brief, dried ginseng berries (5 kg) were ground to powder and extracted twice with 1 L of 95% ethyl alcohol for 2 h in a water bath (60°C). The extracts were concentrated by a vacuum evaporator (Eyela Co., Tokyo, Japan). The lyophilized extract was dissolved in distilled water, and was rinsed 10 times with diethyl ether to remove unnecessary compounds. The water fraction was suspended in distilled water and was adsorbed in a Diaion HP-20 (Mitsubishi Chemical Corporation, Tokyo, Japan) ion exchange resin column. A 30% MeOH fraction, 50% MeOH fraction, 70% MeOH fraction, and 100% MeOH fraction were eluted in the order named. The 30% MeOH fraction was then subjected to an octadecylsilyl (ODS) gel column by gradient elution with 30--100% MeOH, and resulted in four subfractions (F1--F4). The F3 subfraction was rechromatographed on a silica gel column with a mixture of the solvents (CHCl~3~:MeOH:H~2~O = 70:30:4 v/v), and ginsenoside Re was isolated and identified. The authenticity of ginsenoside Re was tested by spectroscopic methods including ^1^H-NMR, ^13^C-NMR, and fast atom bombardment-mass spectrometry (FAB-MS).

2.2. Animals and gastric mucosal lesion induction by C48/80 {#sec2.2}
-----------------------------------------------------------

Male Wistar rats of 6 wk of age were purchased from Samtako (Osan, Korea) and housed in controlled temperature (23 ± 2°C), relative humidity (60 ± 5%), and 12 h light/dark cycle (7:00 [am]{.smallcaps}--7:00 [pm]{.smallcaps}) with free access to water. The experiment was reviewed and approved by the Animal Care and Research Ethics Committee of the Semyung University, Jecheon, South Korea (smecae 08-12-03). Rats were divided into five groups (*n* = 8, respectively): normal (no gastric lesion and administered with distilled water), gastric lesion control (administered with distilled water), gastric lesion positive control (administered with famotidine 4 mg/kg; Nelson Korea Co., Seoul, Korea), and gastric lesion administered with two levels of ginsenoside Re (20 mg/kg and 100 mg/kg). The dosage of 20 mg/kg of ginsenoside Re was chosen from previous published data [@bib15]. The 100 mg/kg dosage was determined to discover the maximum effects of ginsenoside Re. The animals were maintained with free access to rat chow, and famotidine and ginsenoside Re were orally administered with a stomach tube.

After 5 d of sample administration, C48/80 (0.75 mg/kg; Sigma-Aldrich Inc., NY, USA), dissolved in saline, was intraperitoneally injected into the rats fasted for 24 h. The normal group received a saline injection. The animals were sacrificed by decapitation under ether anesthesia 3 h after the C48/80 injection, and blood samples were obtained from the cervical wound.

2.3. Histological Periodic acid Schiff staining {#sec2.3}
-----------------------------------------------

The stomachs were removed, inflated with 10 mL of 0.9% NaCl, and put into 10% formalin for 10 min. The isolated stomachs were cut open along the greater curvature and washed in ice-cold saline. The parts of the mucosa were immediately fixed with 10% formalin solution, and routinely processed for embedding in paraffin wax. The sections were cut 5 μm thick and stained using the Periodic acid Schiff (PAS) method to observe mucus secretion [@bib16].

2.4. Determinations of gastric mucosal adherent mucus and mucosal hexosamine {#sec2.4}
----------------------------------------------------------------------------

The measurement of gastric mucosal adherent mucus was assayed using alcian blue staining [@bib17]. In brief, the parts of the stomach mucosa were rinsed with ice-cold 0.25M sucrose. A 50 mm^2^ (approximately 8 mm-diameter) portion of the glandular region of the stomach was excised with a scalpel, and soaked in 0.1% alcian blue dissolved in 0.16M of sucrose buffered with 0.05M sodium acetate (pH 5.8) for 2 h. The unbound dye was removed using two successive washes with 0.25M sucrose. The dye complex with mucus was extracted using 30% docusate sodium salt (Sigma-Aldrich Inc., NY, USA) for 2 h. After centrifugation at 2,060× *g* for 10 min, the optimal density of the alcian blue solution was measured at 620 nm, and calculated using the calibration curve. The adherent gastric mucosal mucus was expressed as the percentage of the alcian blue adhering to the gastric mucosal surface of the gastric lesion control group.

The measurement of gastric mucosal hexosamine has been used as another indicator of gastric mucus secretion, and was assayed by the method of Neuhaus and Letzring [@bib18]. In brief, gastric mucosal mucin was extracted with Triton X-100 (Sigma Co., St. Louis, MO, USA) and then hydrolyzed with hydrochloric acid. Hexosamine obtained from the hydrolyzed mucin was assayed using acetylacetone and Ehrlich\'s reagent.

2.5. Gastric mucosal enzymes and components {#sec2.5}
-------------------------------------------

The parts of the gastric mucosal tissue were homogenized and centrifuged for 10 min at 9,000× *g* and the supernatant was used for malondialdehyde (MDA), myeloperoxidase (MPO), and xanthine oxidase (XO) analyses. MDA levels of gastric mucosa were determined by the thiobarbituric acid reactive substance (TBARS) colorimetric assay (Synergy2; BioTek Co., USA). Gastric mucosal MPO activity was used to examine the degree of neutrophil infiltration and inflammation. MPO activity was assayed by the method of Suzuki et al [@bib19], measuring the H~2~O~2~-dependent oxidation of tetramethylbenzidine at 37°C. Gastric mucosal XO was assayed according to the method of Hashimoto [@bib20] by measuring the increase in absorbance at 292 nm following the formation of uric acid at 30°C.

2.6. Immunofluorescence analysis {#sec2.6}
--------------------------------

The sections were cut 5 μm thick and mounted on glass slides. The immunofluorescence analysis was performed with mouse monoclonal anti-Bax antibody and rabbit monoclonal anti-Bcl2 antibody (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and fluorescein isothiocyanate (FITC)-conjugated antimouse and antirabbit IgG antibodies, respectively (Sigma Chemical Co., St Louis, MO, USA). The nuclei were counterstained with 1 μg/mL propidium iodide (PI; Sigma Chemical Co.). The fluorescence images were taken with a laser confocal microscope (Fluoview FV1000; Olympus, Tokyo, Japan). The optical density was measured using Bio1d software (Vilber Lourmat, Marne-la-Vallée Cedex, France).

2.7. Laser microdissection and protein extraction {#sec2.7}
-------------------------------------------------

For laser microdissection (LMD), a 10-μm thick section prepared from the same tissue block was attached onto provided slides (Jungwoo F&B Co., Bucheon, Republic of Korea). Sixteen fragments of gastric tissues were collected in a 0.5-mL tube cap using an ION LMD (Jungwoo F&B Co.). Protein extraction was performed as previously described [@bib21]. Briefly, the tissue fragments were deparaffinized and boiled at 100°C in Tris--HCl buffer solutions of pH 8 containing 2% sodium dodecyl sulfate (SDS). Protein concentrations were measured using a DC Protein Assay kit (Bio-Rad, Hercules, CA, USA). Five μL of standards and protein samples were transferred to a 96-well plate and 25 μL of alkaline copper tartrate solution containing Reagent S was added to each well. Then 200 μL of dilute Folin Reagent was added to each well and the 96-well plate was incubated at room temperature. After 15 min, the protein concentrations were measured at 750 nm using an enzyme-linked immunosorbent assay (ELISA) reader (Synergy2; Biotek, Winooski, VT, USA).

2.8. Western blotting analysis {#sec2.8}
------------------------------

Each protein was denatured with 5× sample buffer and boiled for 5 min. Each protein was then fractionated by electrophoresis through a 10% SDS polyacrylamide gel at 100 V for 2 h, and the proteins were transferred onto polyvinylidene fluoride (PVDF) membranes at 100 V for 60 min. Each membrane was blocked with TBST buffer (10 mM Tris--HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20) containing 5% bovine serum albumin (BSA) for 1 h and then incubated with primary antibodies (mouse anti-Bax and rabbit anti-Bcl2 antibodies) in TBST buffer containing 1% BSA at 4°C overnight. The membranes were washed three times with TBST buffer and further incubated with antimouse and anti-rabbit immunoglobulin G (IgG) secondary antibodies conjugated with horseradish peroxidase for 2 h, respectively. Each membrane was filmed with a chemiluminescent imaging system (Fusion SL2; Vilber Lourmat), and analyzed using Bio1d software (Vilber Lourmat).

2.9. Statistical analysis {#sec2.9}
-------------------------

Data are presented as means ± standard deviation (SD). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Duncan\'s multiple range tests. A *p* value \<0.05 was considered to indicate statistical significance. For all analyses, a commercially available statistical package software was used (SPSS version 19; SPSS Inc., Chicago, IL, USA).

3. Results {#sec3}
==========

3.1. Effects of ginsenoside Re on gastric mucosal lesion development {#sec3.1}
--------------------------------------------------------------------

The degree of mucosal damage was examined by histological examination with PAS. The mucus secretion was quantified with alcian blue and hexosamine methods. PAS staining results are shown in [Fig. 1](#fig1){ref-type="fig"}. The apical surface of the mucous cells in normal rats was strongly stained with PAS (arrows in [Fig. 1](#fig1){ref-type="fig"}A) indicating intact gastric mucosa layer. However, PAS reaction was significantly reduced in surface cells of the control group (arrows in [Fig. 1](#fig1){ref-type="fig"}B) showing diffusive erosion of the gastric mucosal cell layer in these rats. PAS reaction increased in famotidine (arrows in [Fig. 1](#fig1){ref-type="fig"}C)- and ginsenoside Re (arrows in [Fig. 1](#fig1){ref-type="fig"}D)-treated rats compared with the control group, suggesting an increase in mucus secretion and alleviation of the erosion in the gastric mucosal cell layer in these groups.

A significant decrease in adherent gastric mucus content was seen in C48/80-induced gastric lesion control rats compared with normal rats ([Table 1](#tbl1){ref-type="table"}). Pre-administration with famotidine and ginsenoside Re significantly attenuated the decrease in adherent gastric mucus content. The effects of ginsenoside Re exhibited dose dependency. Gastric mucosal hexosamine is the best indicator of mucin production, which is the first line of gastric mucosal defense. A significant decrease in mucosal hexosamine content, like in the adherent gastric mucus, was seen in C48/80-induced gastric lesion control rats compared with normal rats ([Table 1](#tbl1){ref-type="table"}). Pre-administration with famotidine and ginsenoside Re significantly attenuated the decrease in mucosal hexosamine content. These effects of ginsenoside Re exhibited dose dependency.

3.2. Effects of ginsenoside Re on gastric mucosal lesion development {#sec3.2}
--------------------------------------------------------------------

Gastric mucosal MDA content, MPO, and XO activities significantly increased in C48/80-treated control rats compared to those of the normal group ([Table 2](#tbl2){ref-type="table"}). The MDA content, MPO, and XO activities in the C48/80-treated control group were 3.6, 2.3, and 1.4 times higher, respectively, than those in the normal group. Pre-administered ginsenoside Re significantly attenuated these parameters.

3.3. Bax and Bcl2 expressions in mucosa {#sec3.3}
---------------------------------------

Immunofluorescence staining clearly showed that Bax was expressed and limited to the cytosol of the gastric mucosal cells ([Fig. 2](#fig2){ref-type="fig"}). Bax positive cells were found predominantly in part of the gastric gland (arrow in [Fig. 2](#fig2){ref-type="fig"}B). The Bax staining in submucosa and muscularis externa was very strong (arrowhead in [Fig. 2](#fig2){ref-type="fig"}B). Bax staining decreased in famotidine (positive control, arrow in [Fig. 2](#fig2){ref-type="fig"}C)- and ginsenoside Re (arrow in [Fig. 2](#fig2){ref-type="fig"}D)-treated rats compared with the control group suggesting the alleviation of apoptotic damage in the gastric mucosal cell layer in these groups. By contrast, Bcl2 positive cells were found predominantly in part of the normal gastric gland (arrow in [Fig. 3](#fig3){ref-type="fig"}A). Bcl2 staining in submucosa and muscularis externa was extremely strong in the normal group (arrowhead in [Fig. 3](#fig3){ref-type="fig"}A). Bcl2 staining became weak in both gastric mucosa and submucosa in the control group (arrow and arrowhead in [Fig. 3](#fig3){ref-type="fig"}B). Famotidine and ginsenoside Re attenuated the diminishment of the Bcl2 staining in both gastric mucosa and submucosa (arrow and arrowhead in [Fig. 3](#fig3){ref-type="fig"}C and D).

3.4. Bax and Bcl2 western blotting in mucosa {#sec3.4}
--------------------------------------------

Parts of the gastric gland, submucosa, and muscularis externa were microdissected ([Fig. 4](#fig4){ref-type="fig"}A) and the proteins were extracted. Bax protein increased in the C48/80-treated control and decreased in the famotidine- and ginsenoside Re-treated groups. By contrast, Bcl2 protein decreased in the C48/80-treated control and increased in the famotidine- and ginsenoside Re-treated groups ([Fig. 4](#fig4){ref-type="fig"}B). The ratio of Bax and Bcl2 significantly increased in the C48/80-treated control group compared with the normal group ([Fig. 4](#fig4){ref-type="fig"}C, *p* \< 0.05). The famotidine- and ginsenoside Re-treated groups showed significantly decreased Bax/Bcl2 ratios compared with the C48/80-treated control (*p* \< 0.05).

4. Discussion {#sec4}
=============

Ginsenoside Re showed multiple pharmacological activities including antidiabetic [@bib3], antiobese [@bib4], antioxidant, anticancer [@bib22], memory-enhancing [@bib23], and anti-inflammatory effects [@bib24], and inhibitory activities on histamine release [@bib7]. Histamine is an organic nitrogen compound involved in regulating physiological function in the digestive system and local immune responses. There are four types of histamine receptors (H~1~--H~4~). Among them, the H~2~ receptor antagonists are used in the treatment of peptic ulcer disease, gastroesophageal reflux disease, and dyspepsia, as well as in the prevention of stress ulcers [@bib25]. Famotidine, an H~2~ receptor antagonist with a thiazole nucleus, is approximately 7.5 times more potent than ranitidine and 20 times more potent than cimetidine on an equimolar basis [@bib11]. Famotidine was, therefore, used as a positive control in the present study.

Among the variety of biological activities of ginsenoside Re reported *in vitro* and in animal models, we have noticed the antihistamine and anti-inflammatory activities [@bib7]. In this study, we attempted to examine the effect of ginsenoside Re on acute gastric lesion progression induced by C48/80. The C48/80 promotes histamine release [@bib26] and causes acute gastric mucosal lesions. The model of acute gastric mucosal lesions in rats treated once with C48/80 has been thought to be important for clarifying the roles of oxidative stress and inflammation in the pathogenesis of gastritis in humans [@bib27].

The results of the present study have clearly shown that ginsenoside Re administered orally to C48/80-treated rats protects gastric mucosal lesion progression, and its potency is similar to famotidine. Pre-administration of ginsenoside Re ameliorated gastric mucosal damage, mucus secretion, MDA content, MPO, and XO activities. Mucus secretion is a crucial factor in the protection of gastric mucosa from gastric lesions and has been regarded as an important defensive factor in the gastric mucus barrier. A decrease in the synthesis of mucus has been implicated in the etiology of gastric ulcers [@bib28]. The mucus layer protects the newly formed cells against the damage caused by acidic pH and the proteolytic potential of gastric secretions [@bib29].

The wide distribution of adherent mucus content in the gastrointestinal tract plays a pivotal role in cytoprotection and repair of the gastric mucosa [@bib30]. The results showed that severity of erosion induced by C48/80 treatment was alleviated by ginsenoside Re administration, and gastric mucosal damage and mucus secretion assessed by alcian blue staining and gastric mucosal hexosamine were dose-dependently improved by ginsenoside Re administration.

Ohta et al [@bib14] suggested that neutrophil infiltration plays a critical role in C48/80-induced acute gastric mucosal lesion formation and progression. In the present study, ginsenoside Re normalized the increased gastric mucosal neutrophil infiltration assessed by MPO activity. The level of MPO activity is directly proportional to numbers of neutrophils, and Krawisz et al [@bib31] suggested that MPO activity can be used to quantitate inflammation. Therefore, the results of the present study suggest the suppressive effect on neutrophil infiltration and anti-inflammatory action of ginsenoside Re.

It has been shown that changes in gastric mucosal reactive oxygen species (ROS) and neutrophil infiltration into gastric mucosal tissues are closely related to the development of gastric mucosal lesions in rats with a single C48/80 treatment [@bib27]. XO generates ROS during the oxidation of hypoxanthine or xanthine [@bib32], and Ohta et al [@bib33] suggested that the xanthine--XO system in the gastric mucosal tissue participates in the progression of gastric mucosal lesion. In the present study, increased MPO activity---an index of neutrophil infiltration---of the gastric lesion control group was reduced, and ROS-related parameters such as MDA content and XO activity were normalized by ginsenoside Re administration. From the present study, it seems likely that administration of ginsenoside Re exerts a preventive effect on the progression of C48/80-induced acute gastric mucosal lesions by protecting the gastric mucosal barrier and tissue against the attack of ROS derived from infiltrated neutrophils and the xanthine--XO system through preservation of gastric mucus.

The protein encoded by the *Bcl2* gene is a regulator of programmed cell death and apoptosis. The cell survival-promoting activity of this protein is contrary to the cell death-promoting activity of Bax, a homologous protein that forms heterodimers with Bcl2 and accelerates rates of cell death [@bib34]. The expression of Bax is upregulated by the response of the cell to stress [@bib35]. Bax protein significantly increased 3 h after hypoxic--ischemic brain injury in neonatal brain tissue [@bib36] and it increased in gastric mucosa after ischemia--reperfusion damage [@bib37]. In the present results, the predominant increase of Bax expression was discovered after C48/80-induced acute gastritis. We have observed that the increased Bax expression by C48/80 treatment was attenuated when ginsenoside Re was administered. In contrast to Bax, Bcl2 expression decreased after C48/80 induced acute gastritis and ginsenoside Re attenuated the diminution. In Western blotting analysis, the Bax/Bcl2 ratio result also confirmed the protective effects of ginsenoside Re on C48/80-induced acute gastritis.

In conclusion, the results of the present study indicate that ginsenoside Re exerts a preventive effect on the progression of C48/80-induced acute gastric mucosal lesion in rats, possibly by inducing mucus secretion and attenuating enhanced neutrophil infiltration, inflammation, and oxidative stress in gastric mucosa.
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![Histological analysis of gastric mucosa of rat stained with PAS. (A) Normal group: surface mucous cells (arrows) were strongly stained with PAS. (B) Gastric lesion control group: the PAS reaction was reduced in surface cells (arrows). (C) Gastric lesion positive control group (famotidine, 4 mg/kg): the PAS reaction remained in surface cells (arrows). (D) Gastric lesion treated with ginsenoside Re (100 mg/kg): the PAS reaction remained in surface cells (arrows). Scale bars = 100 μm. PAS, Periodic acid Schiff.](gr1){#fig1}

![Immunofluorescence analysis of Bax in the gastric mucosa of rats. The Bax positive cells were probed with anti-Bax monoclonal antibody in rat gastric mucosa (green color). Nuclear counterstaining was performed with propidium iodide (PI). (A) Normal group: Bax staining of surface mucous cells (arrows) showed up faintly. (B) Gastric lesion control group: Bax staining of surface mucous cells (arrows) showed up brightly. (C) Gastric lesion positive control group (famotidine, 4 mg/kg): Bax staining of surface mucous cells (arrows) was diminished. The Bax staining of submucosa and muscularis externa (arrowheads) was identical to that carried out on the mucosa. (D) Gastric lesion treated with ginsenoside Re (100 mg/kg): Bax staining of surface mucous cells (arrows) was diminished. The Bax staining of submucosa and muscularis externa (arrowheads) was identical to that carried out on the mucosa. Scale bars = 100 μm. \* *p* \< 0.05 vs. normal. \*\* *p* \< 0.05 vs. control. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr2){#fig2}

![Immunofluorescence analysis of Bcl2 in the gastric mucosa of rats. The Bcl2 positive cells were probed with anti-Bcl2 monoclonal antibody in rat gastric mucosa (green color). Nuclear counterstaining was performed with propidium iodide (PI). (A) Normal group: Bcl2 staining of surface mucous cells (arrows) showed up brightly. (B) Gastric lesion control group: Bcl2 staining of surface mucous cells (arrows) showed up faintly. (C) Gastric lesion positive control group (famotidine, 4 mg/kg): Bcl2 staining of surface mucous cells (arrows) was brightened. The Bcl2 staining of submucosa and muscularis externa (arrowheads) was identical to that carried out on the mucosa. (D) Gastric lesion treated with ginsenoside Re (100 mg/kg): Bcl2 staining of surface mucous cells (arrows) was brightened. The Bcl2 staining of submucosa and muscularis externa (arrowheads) was identical to that carried out on the mucosa. Scale bars = 100 μm. \* *p* \< 0.05 vs. normal. \*\* *p* \< 0.05 vs. control. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr3){#fig3}

![Representative results of Western blotting of Bax and Bcl2. The cells of interest were identified with (A, Prior to) laser microdissection, (A, Cutting) cut away with a near-IR laser, and (A, After) dropped away from the tissue. (B) Western blotting shows changes in the expression levels of Bax and Bcl2 in the microdissected gastric tissue. (C) A histogram of relative changes in the expression levels of the two proteins in the gastric tissues as determined by densitometric analysis. Scale bars = 200 μm. \* *p* \< 0.05 vs. normal. \*\* *p* \< 0.05 vs. control.](gr4){#fig4}

###### 

Effects of Ginsenoside Re on Adherent Gastric Mucus and Mucosal Hexosamine Content

  Group                                           Adherent gastric mucus (% alcian blue/g tissue)   Mucosal hexosamine (mg/g tissue)
  ----------------------------------------------- ------------------------------------------------- ----------------------------------
  Normal                                          100.0 ± 4.7\*\*                                   3.5 ± 0.1\*\*
  Control                                         38.2 ± 5.0\*                                      1.6 ± 0.2\*
  Famotidine[1)](#tbl1fn1){ref-type="table-fn"}   68.5 ± 12.3\*^,^\*\*                              2.5 ± 0.4\*^,^\*\*
  Re 20[2)](#tbl1fn2){ref-type="table-fn"}        59.5 ± 8.0\*^,^\*\*                               2.0 ± 0.2\*^,^\*\*
  Re 100[3)](#tbl1fn3){ref-type="table-fn"}       64.6 ± 9.2\*^,^\*\*                               2.4 ± 0.3\*^,^\*\*

Data are expressed as mean ± standard deviation (SD; *n* = 10).

\* *p* \< 0.05 vs. normal.

\*\* *p* \< 0.05 vs. control.

Famotidine: positive control (4 mg/kg).

Re 20: ginsenoside Re treated at 20 mg/kg.

Re 100: ginsenoside Re treated at 100 mg/kg.

###### 

Effects of Ginsenoside Re on Gastric Mucosal MDA Contents and MPO and XO Activities

  Group                                           MDA (μM/mg)          MPO (%)                XO (μU/mg)
  ----------------------------------------------- -------------------- ---------------------- -----------------------
  Normal                                          1.1 ± 0.3\*\*        100.0 ± 9.9\*\*        148.9 ± 24.9\*\*
  Control                                         4.0 ± 0.8\*          144.9 ± 9.0\*          340.2 ± 11.7\*
  Famotidine[1)](#tbl2fn1){ref-type="table-fn"}   1.5 ± 0.3\*\*        113.3 ± 7.3\*^,^\*\*   251.6 ± 18.7\*^,^\*\*
  Re 20[2)](#tbl2fn2){ref-type="table-fn"}        2.8 ± 0.5\*^,^\*\*   135.1 ± 10.4\*         170.9 ± 20.9\*\*
  Re 100[3)](#tbl2fn3){ref-type="table-fn"}       1.8 ± 0.3\*^,^\*\*   116.2 ± 8.1\*^,^\*\*   231.0 ± 22.4\*^,^\*\*

Data expressed as mean ± SD (*n* = 10).

\* *p* \< 0.05 vs. normal.

\*\* *p* \< 0.05 vs. control.

MDA, malondialdehyde; MPO, myeloperoxidase; SD, standard deviation; XO, xanthine oxidase.

Famotidine: positive control (4 mg/kg).

Re 20: ginsenoside Re treated at 20 mg/kg.

Re 100: ginsenoside Re treated at 100 mg/kg.
